Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
February 18 2021 - 4:05PM
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of Haduvio™ (nalbuphine ER) to treat serious
neurologically mediated conditions, today announced that management
will participate in a virtual fireside chat, as well as host
virtual investor meetings, at the 10th Annual SVB Leerink Global
Healthcare Conference on February 25, 2021.
Presentation Time: 4:20 p.m. ET
A live webcast of the virtual fireside chat can be accessed by
visiting ‘News & Events’ in the ‘Investors & News’ section
on the Company’s website at www.trevitherapeutics.com. An archived
replay of the webcast will also be available for 30 days on the
Company’s website following the conference.
The Company’s corporate presentation is posted to its website in
the ‘Investors & News’ section under ‘News & Events’.
About Trevi Therapeutics, Inc.Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of Haduvio
to treat serious neurologically mediated
conditions. Trevi is currently developing Haduvio for the
treatment of chronic pruritus, chronic cough in patients with
idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia
(LID) in patients with Parkinson’s disease. These conditions share
a common pathophysiology that is mediated through opioid receptors
in the central and peripheral nervous systems. Trevi is
currently conducting a Phase 2b/3 clinical trial of Haduvio,
referred to as the PRISM trial, in patients with severe pruritus
associated with prurigo nodularis and a Phase 2 trial for chronic
cough in patients with IPF.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About HADUVIO Haduvio is an oral extended
release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe.
The ĸ- and µ-opioid receptors are known to be critical mediators of
itch, cough and certain movement disorders. Nalbuphine’s mechanism
of action also mitigates the risk of abuse associated with µ-opioid
agonists because it antagonizes, or blocks, µ-opioid receptors.
Nalbuphine is currently the only opioid approved for marketing that
is not classified as a controlled substance in the United
States and most of Europe. Trevi intends to
propose Haduvio as the trade name for the nalbuphine ER
investigational product. Haduvio is an investigational drug product
and its safety and efficacy have not been fully evaluated by any
regulatory authority.
Investor ContactChris Seiter, Chief Financial
OfficerTrevi Therapeutics,
Inc.203-304-2499chris.seiter@trevitherapeutics.com
Media ContactRosalia
Scampoli914-815-1465rscampoli@marketcompr.com
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024